Compare Incyte Corporation (INCY) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs State Street SPDR S&P Homebuilders ETF — how do they compare? Incyte Corporation trades at $118.02 (market cap $23.11B), while State Street SPDR S&P Homebuilders ETF trades at $105.81. The key difference: Incyte Corporation is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| INCY | XHB | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $118.52 | $121.36 |
52-Week Low | $67.38 | $94.86 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
XHB trades at $106.07, down 2.01% today amid a bearish technical signal with moving averages indicating selling pressure. The ETF faces mixed housing data, with June home sales declining but new legislation potentially boosting homebuilders. Key support lies at $104, while resistance is at $110. Financial ratios are unavailable, but sentiment is influenced by macroeconomic factors like mortgage rates and housing affordability.
Outlook remains cautious due to high mortgage rates and volatile home sales, though regulatory support offers upside potential. Risks include interest rate sensitivity and economic slowdowns. Investors should weigh technical weakness against long-term housing demand drivers for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
